De vertaling van deze pagina is experimenteel en in ontwikkeling. Uw is welkom!
Alibaba Health Information Technology Inkomsten in het verleden
Verleden criteriumcontroles 4/6
Alibaba Health Information Technology is de winst gegroeid met een gemiddeld jaarlijks percentage van 52.3%, terwijl de Consumer Retailing industrie de winst jaarlijks groeide met 18.3%. De inkomsten zijn gegroeid met een gemiddelde snelheid van 28.2% per jaar. Het rendement op eigen vermogen van Alibaba Health Information Technology is 6.1%, en het heeft een nettomarge van 3.3%.
Belangrijke informatie
52.3%
Groei van de winst
51.2%
Groei van de winst per aandeel
| Consumer Retailing Groei van de industrie | 28.3% |
| Inkomstengroei | 28.2% |
| Rendement op eigen vermogen | 6.1% |
| Nettomarge | 3.3% |
| Laatste winstupdate | 31 Mar 2024 |
Recente prestatie-updates uit het verleden
Recent updates
What Does Alibaba Health Information Technology Limited's (HKG:241) Share Price Indicate?
Sep 23
Alibaba Health Information Technology (HKG:241) Is Looking To Continue Growing Its Returns On Capital
Jul 03After Leaping 26% Alibaba Health Information Technology Limited (HKG:241) Shares Are Not Flying Under The Radar
Jun 07Alibaba Health Information Technology's (HKG:241) Solid Earnings Are Supported By Other Strong Factors
Jun 06Risks Still Elevated At These Prices As Alibaba Health Information Technology Limited (HKG:241) Shares Dive 26%
Apr 21Is Now The Time To Look At Buying Alibaba Health Information Technology Limited (HKG:241)?
Apr 16Alibaba Health Information Technology (HKG:241) Might Have The Makings Of A Multi-Bagger
Mar 29Is There An Opportunity With Alibaba Health Information Technology Limited's (HKG:241) 36% Undervaluation?
Mar 12With A 25% Price Drop For Alibaba Health Information Technology Limited (HKG:241) You'll Still Get What You Pay For
Jan 17Is Now An Opportune Moment To Examine Alibaba Health Information Technology Limited (HKG:241)?
Jan 07Returns On Capital Are Showing Encouraging Signs At Alibaba Health Information Technology (HKG:241)
Dec 15Shareholders Should Be Pleased With Alibaba Health Information Technology Limited's (HKG:241) Price
Sep 28Alibaba Health Information Technology Limited's (HKG:241) Intrinsic Value Is Potentially 25% Below Its Share Price
Jul 02Is Alibaba Health Information Technology Limited (HKG:241) Potentially Undervalued?
Jun 11Estimating The Fair Value Of Alibaba Health Information Technology Limited (HKG:241)
Jun 22Is There An Opportunity With Alibaba Health Information Technology Limited's (HKG:241) 49% Undervaluation?
Dec 01Alibaba Health Information Technology (HKG:241) Is Looking To Continue Growing Its Returns On Capital
Oct 15Estimating The Fair Value Of Alibaba Health Information Technology Limited (HKG:241)
Aug 12Alibaba Health Information Technology (HKG:241) Is Doing The Right Things To Multiply Its Share Price
Jun 25These Analysts Just Made A Huge Downgrade To Their Alibaba Health Information Technology Limited (HKG:241) EPS Forecasts
May 30Earnings Report: Alibaba Health Information Technology Limited Missed Revenue Estimates By 6.8%
May 27The Return Trends At Alibaba Health Information Technology (HKG:241) Look Promising
Mar 23Should You Be Adding Alibaba Health Information Technology (HKG:241) To Your Watchlist Today?
Mar 05How Much Are Alibaba Health Information Technology Limited (HKG:241) Insiders Taking Off The Table?
Feb 15Are Alibaba Health Information Technology's (HKG:241) Statutory Earnings A Good Reflection Of Its Earnings Potential?
Jan 31
If You Had Bought Alibaba Health Information Technology (HKG:241) Stock Three Years Ago, You Could Pocket A 457% Gain Today
Dec 31Has Alibaba Health Information Technology Limited's (HKG:241) Impressive Stock Performance Got Anything to Do With Its Fundamentals?
Dec 16Will Alibaba Health Information Technology's (HKG:241) Growth In ROCE Persist?
Dec 01Opbrengsten en kosten
Hoe Alibaba Health Information Technology geld verdient en uitgeeft. Gebaseerd op laatst gerapporteerde winst, op LTM-basis.
Inkomsten en omzetgeschiedenis
| Datum | Inkomsten | Inkomsten | G+A Uitgaven | R&D-uitgaven |
|---|---|---|---|---|
| 31 Mar 24 | 27,027 | 883 | 4,550 | 705 |
| 31 Dec 23 | 27,623 | 851 | 4,943 | 689 |
| 30 Sep 23 | 28,218 | 817 | 5,336 | 673 |
| 30 Jun 23 | 27,491 | 675 | 5,196 | 675 |
| 31 Mar 23 | 26,763 | 536 | 5,055 | 678 |
| 31 Dec 22 | 24,742 | 332 | 4,701 | 704 |
| 30 Sep 22 | 22,720 | 128 | 4,346 | 730 |
| 30 Jun 22 | 21,649 | -69 | 4,410 | 729 |
| 31 Mar 22 | 20,578 | -266 | 4,474 | 729 |
| 31 Dec 21 | 19,146 | -216 | 4,171 | 623 |
| 30 Sep 21 | 17,714 | -167 | 3,868 | 517 |
| 30 Jun 21 | 16,616 | 91 | 3,501 | 470 |
| 31 Mar 21 | 15,518 | 349 | 3,135 | 424 |
| 31 Dec 20 | 14,080 | 313 | 2,836 | 385 |
| 30 Sep 20 | 12,642 | 278 | 2,537 | 347 |
| 30 Jun 20 | 11,119 | 136 | 2,289 | 300 |
| 31 Mar 20 | 9,596 | -7 | 2,041 | 253 |
| 31 Dec 19 | 8,465 | -3 | 1,833 | 252 |
| 30 Sep 19 | 7,334 | 1 | 1,624 | 250 |
| 30 Jun 19 | 6,215 | -40 | 1,416 | 235 |
| 31 Mar 19 | 5,096 | -82 | 1,208 | 219 |
| 31 Dec 18 | 4,264 | -91 | 1,034 | 194 |
| 30 Sep 18 | 3,432 | -100 | 859 | 169 |
| 30 Jun 18 | 2,937 | -104 | 760 | 147 |
| 31 Mar 18 | 2,443 | -107 | 661 | 126 |
| 31 Dec 17 | 1,876 | -152 | 563 | 123 |
| 30 Sep 17 | 1,310 | -196 | 465 | 120 |
| 30 Jun 17 | 892 | -202 | 371 | 114 |
| 31 Mar 17 | 475 | -208 | 276 | 109 |
| 31 Dec 16 | 285 | -201 | 233 | 99 |
| 30 Sep 16 | 94 | -194 | 191 | 90 |
| 30 Jun 16 | 76 | -193 | 182 | 83 |
| 31 Mar 16 | 57 | -192 | 173 | 76 |
| 31 Dec 15 | 44 | -173 | 175 | 68 |
| 30 Sep 15 | 32 | -154 | 177 | 60 |
| 30 Jun 15 | 31 | -118 | 145 | 47 |
| 31 Mar 15 | 30 | -81 | 113 | 34 |
| 31 Dec 14 | 31 | -60 | 74 | 29 |
| 30 Sep 14 | 31 | -39 | 35 | 23 |
| 30 Jun 14 | 27 | -36 | 35 | 19 |
| 31 Mar 14 | 22 | -31 | 33 | 14 |
| 31 Dec 13 | 16 | -35 | 34 | 7 |
Kwaliteitswinsten: 241 heeft een grote eenmalige verlies van CN¥293.9M wat gevolgen heeft voor de financiële resultaten van de laatste 12 maanden tot 31st March, 2024.
Groeiende winstmarge: De huidige netto winstmarges (3.3%) 241 } zijn hoger dan vorig jaar (2%).
Analyse vrije kasstroom versus winst
Analyse van de winstgroei in het verleden
Winsttrend: 241 is de afgelopen 5 jaar winstgevend geworden en heeft de winst met 52.3% per jaar laten groeien.
Versnelling van de groei: De winstgroei van 241 over het afgelopen jaar ( 64.9% ) overtreft het 5-jarig gemiddelde ( 52.3% per jaar).
Winst versus industrie: De winstgroei 241 over het afgelopen jaar ( 64.9% ) overtrof de Consumer Retailing -sector -8.4%.
Rendement op eigen vermogen
Hoge ROE: Het Rendement op eigen vermogen ( 6.1% ) van 241 wordt als laag beschouwd.